Wolverine Legal Status, FDA 503A Category, and Compounding Access

Wolverine legal status: where the two records stand today

Wolverine legal status is a status story, and the momentum is forward. Access to compounded BPC-157 TB-500 is under active FDA review, and it may expand in 2026 — because the FDA Pharmacy Compounding Advisory Committee (PCAC) has a meeting scheduled for July 23-24, 2026 at which both of the blend's components are listed as bulk drug substances being considered for inclusion on the 503A Bulks List ^[12]. That is the live development worth leading with.

The present-tense fact underneath it is narrower. Today, both constituents of the Wolverine blend are research peptides in FDA's 503A "Category 2" — bulk substances that FDA has identified as potentially presenting significant safety risks — effective with the September 29, 2023 update to the nominated-substances list ^[10][11]. Category 2 substances are not covered by FDA's enforcement-discretion policy for 503A compounding, so compounding-pharmacy access is currently restricted ^[10]. Neither peptide is an FDA-approved drug, and the blend has no approved therapeutic indication.

Both things are true at once: the current classification restricts routine compounding, and that classification is precisely what is under scheduled review. Nothing here predicts the meeting's outcome. A PCAC discussion is advisory — a step in evaluation, not a final listing decision ^[12].

What FDA 503A Category 2 means for BPC-157 and TB-500

Under the Federal Food, Drug, and Cosmetic Act, compounding runs through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight ^[10]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list; otherwise it must be nominated and evaluated by FDA, with input from PCAC ^[10].

FDA's interim policy sorted nominated substances into categories. Category 1 substances "may be eligible" for the bulks list and are covered by FDA's enforcement-discretion policy while under evaluation. Category 2 substances were nominated with enough information to evaluate but were identified by FDA as raising significant safety risks — and FDA stated it would consider taking action against a compounder for compounding with a Category 2 substance ^[10]. Both BPC-157 and TB-500 are in Category 2, with FDA citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization ^[11].

Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by PCAC. Being discussed by PCAC is a step in that evaluation — not a final listing decision, and not a change in current status ^[12].

Both components are on the July 23-24, 2026 PCAC agenda

There is no component carve-out in the Wolverine blend. Both records are under the same scheduled review. FDA's public advisory-committee calendar lists the BPC-157 entries ("BPC-157 (free base)" / "BPC-157 acetate") and the TB-500 entries ("TB-500 (free base)" / "TB-500 acetate") among the bulk drug substances being considered for inclusion on the 503A Bulks List at the July 23-24, 2026 PCAC meeting ^[12].

FDA's own Category 2 list also establishes the identity of the second record: it names the entry "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — the same Ac-LKKTETQ heptapeptide that is one of the two peptides in this blend ^[11]. So both BPC-157 and TB-500 (the thymosin beta-4 fragment, LKKTETQ) are currently Category 2, and both are on this one scheduled agenda as bulks-list candidates.

What the agenda does not do is decide anything. The outcome of the July 2026 meeting is unknown; FDA's calendar confirms only that these substances are scheduled for discussion as candidates ^[12]. No reclassification has occurred, none is dated, and none is certain.

How legally compounded peptide access works

Independent of any single substance's status, the lawful pathway for a compounded medication in the U.S. is well defined. A patient is first evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate ^[13]. Telehealth is one channel for that prescriber-evaluation step; it is a route to a licensed-prescriber consultation, not a separate legal status, and it does not change which substances may be compounded ^[13].

If a compounded preparation is appropriate and lawful, the prescriber issues a valid, patient-specific prescription. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, an FDA-registered 503B outsourcing facility ^[13].

The ingredient-eligibility caveat is the gate. A compounder may use a requested active ingredient only if it is eligible under the 503A/503B bulk-substance rules — and ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands ^[13]. That is the current position for both BPC-157 and TB-500. This page is general information about the regulatory landscape, not medical or legal advice, and not an offer to supply any substance.

WADA status of both constituents

Outside the compounding question, both constituents are prohibited in sport. The World Anti-Doping Agency lists BPC-157 under its S0 non-approved-substances category, and TB-500 / Thymosin Beta-4 falls under prohibited peptide, growth-factor, and tissue-repair categories. For athletes subject to anti-doping rules, the blend is banned in and out of competition for the relevant classes. This is a status fact, not a recommendation; the page does not advise on use.